ArticleAmerican journal of ophthalmology2007
Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up.
Article in American journal of ophthalmology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00589628 (Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis), which is not on this map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis.BMC ophthalmology · 2023Pooled it
- Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis.Orphanet journal of rare diseases · 2020Pooled it
- Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis.Arthritis care & research · 2019Guideline
- Pars planitis: a study of clinical features and treatment results.BMC ophthalmology · 2026Article
- Systemic Immunomodulatory Therapy, Anterior Chamber Inflammation, and the Use of Topical Corticosteroids in Juvenile Idiopathic Arthritis-Associated Uveitis: A Long-Term Real-Life Observational Study.Journal of clinical medicine · 2026Article
- The effect of anti-TNF α therapy on refractory non-infectious pediatric uveitis in Saudi Arabia.BMC ophthalmology · 2026Article
- Use of immunomodulators in non-infectious uveitis: lights and shadows.Eye (London, England) · 2024Review
- Adalimumab to treat noninfectious pediatric chronic anterior uveitis: a case series.International ophthalmology · 2024Article
- Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry.Ophthalmology and therapy · 2024Article
- Ocular involvement in pediatric Behçet's disease: is it different than in adults? (a short case series and mini review).BMC ophthalmology · 2023Review
- Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review.Pharmaceutics · 2023Review
- Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice.Rheumatology and therapy · 2022Review
- Quiescence and Subsequent Anterior Chamber Inflammation in Adalimumab-treated Pediatric Noninfectious Uveitis.Korean journal of ophthalmology : KJO · 2020Article
- Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy.Crohn's & colitis 360 · 2020Review
- Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis.Pediatric rheumatology online journal · 2019Article
- Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis.Journal of ophthalmic inflammation and infection · 2019Article
- Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.Eye (London, England) · 2019Article
- S100A12 and vascular endothelial growth factor can differentiate Blau syndrome and familial Mediterranean fever from systemic juvenile idiopathic arthritis.Clinical rheumatology · 2019Article
- An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.Current treatment options in rheumatology · 2017Article
- The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.Paediatric drugs · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo assess a response to infliximab therapy in childhood uveitis.
designRetrospective case series.
methodsWe reviewed the course of 16 children with noninfectious uveitis treated with infliximab at an academic medical center. Outcome measures included incidence of uveitis recurrences, proportion of patients achieving zero or two-step decline in ocular inflammation, visual acuity, and proportion discontinuing topical glucocorticoids at zero, three, six, nine, and 12 months of therapy.
resultsOf sixteen children (29 affected eyes) with median age 11 years, six had associated extraocular inflammatory conditions. Fifteen of 16 were treated with concomitant methotrexate. Median follow-up was 26 months and median maintenance infliximab dose was 8.2 mg/kg. The median interval between infliximab infusions was 5.6 weeks. At one year, 64% achieved zero ocular inflammation, and 79% had zero inflammation or a two-step decline in inflammation. Topical glucocorticoids were discontinued in 69%, and 58% remained free of uveitis recurrence at one year. Visual acuity remained stable. Infliximab was discontinued in two children, one because of inefficacy and the other because of parental concern about potential side effects. No adverse events occurred.
conclusionsSixteen children with chronic, noninfectious uveitis tolerated chronic methotrexate and infliximab therapy. Visual acuity remained stable, control of ocular inflammation improved, and reliance on topical glucocorticoids decreased. High infliximab doses and frequent dosing intervals were necessary to control uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.